Katalin Karikó, who is sharing the Nobel Prize in medicine for her work with mRNA vaccines, says she was previously demoted by the University of Pennsylvania for her research in that area. “If you know about 10 years ago, I was here in October because I was kicked out from UPenn, was forced to retire,”…
From developing a one-and-done coronavirus shot to overcoming misinformation and global vaccine inequity, Nobel prize winner Drew Weissman says that at 64, he's only "speeding up."- Misinformation and equity -
Of course, scientific advances need to reach people to make a difference, and to this end Weissman is part of a group working to tackle hesitancy at the global level.
SEOUL, South Korea, August 09, 2023 Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 9th of August that an Investigational New Drug (IND) application has been approved by the Ministry of Food and Drug Safety (MFDS) for mRNA vaccine LEM-mR203 with its nano-drug delivery technology, DegradaBALL® on 21st of July.
CanSino Biologics has agreed with AstraZeneca to provide "contract development and manufacturing services" to support the Anglo-Swedish drugmaker's messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday. In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca. AstraZeneca did not have an immediate comment on the announcement.
China's Stemirna Therapeutics said on Wednesday it had suspended work at a factory it had planned to use to manufacture its COVID-19 vaccine candidate that uses messenger RNA (mRNA) technology, citing a lack of demand. Stemirna, whose backers include private equity firm HongShan, previously known as Sequoia Capital China, said in a statement it had only been testing production and would now focus on research instead. The company had planned to have the capacity to produce 400 million doses of its vaccine candidate a year via two factories, the second of which had not started operations.